多格列艾汀用于未使用降糖药的2型糖尿病患者:一项随机、双盲、安慰剂对照3期试验
该随机、双盲、安慰剂对照3期试验纳入463例未使用降糖药的2型糖尿病患者,按2:1随机分配至多格列艾汀组或安慰剂组,双盲治疗24周,随后所有患者开放标签接受多格列艾汀治疗28周。主要疗效终点为糖化血红蛋白自基线至第24周的变化,多格列艾汀组最小二乘均值变化为-1.07%(95%CI -1.19%, -0.95%),安慰剂组为-0.50%(95%CI -0.68%, -0.32%),估计治疗差异为-0.57%(95%CI -0.79%, -0.36%;P < 0.001)。两组不良事件发生率相似,多格列艾汀组未发生严重低血糖事件或药物相关严重不良事件。
要点
- 多格列艾汀组第24周糖化血红蛋白较基线下降-1.07%,安慰剂组下降-0.50%,估计治疗差异-0.57%(P < 0.001)。
- 两组不良事件发生率相似,多格列艾汀组无严重低血糖事件或药物相关严重不良事件。
- 多格列艾汀改善未使用降糖药的2型糖尿病患者的血糖控制,耐受性和安全性良好。
核心结论
- 多格列艾汀改善未使用降糖药的2型糖尿病患者的血糖控制,并显示出良好的耐受性和安全性。
研究设计与样本
- 随机、双盲、安慰剂对照3期临床试验,纳入463例未使用降糖药的2型糖尿病患者,按2:1随机分配至多格列艾汀组或安慰剂组,双盲治疗24周,随后所有患者开放标签接受多格列艾汀治疗28周。
主要发现
- 第24周糖化血红蛋白自基线的最小二乘均值变化(95%置信区间)在多格列艾汀组为-1.07%(-1.19%, -0.95%),在安慰剂组为-0.50%(-0.68%, -0.32%);估计治疗差异为-0.57%(95%置信区间:-0.79%, -0.36%;P < 0.001)。
- 两组不良事件发生率相似。
- 多格列艾汀组未发生严重低血糖事件或药物相关严重不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a glucose-dependent manner, improves glucose-stimulated insulin secretion and demonstrates effects on glycemic control in patients with T2D. We report the findings of a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the efficacy and safety of dorzagliatin in patients with T2D. Eligible drug-naïve patients with T2D (n = 463) were randomly assigned to the dorzagliatin or placebo group at a ratio of 2:1 for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin from baseline to week 24. Safety was assessed throughout the trial. At week 24, the least-squares mean change in glycated hemoglobin from baseline (95% confidence interval) was -1.07% (-1.19%, -0.95%) in the dorzagliatin group and -0.50% (-0.68%, -0.32%) in the placebo group (estimated treatment difference, -0.57%; 95% confidence interval: -0.79%, -0.36%; P < 0.001). The incidence of adverse events was similar between the two groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin group. In summary, dorzagliatin improved glycemic control in drug-naïve patients with T2D and showed a good tolerability and safety profile.
引用
- Zhu D, Li X, Ma J, et al. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2022. PMID: 35551294. doi:10.1038/s41591-022-01802-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。